Low-dose intravenous ketamine was safe and well tolerated in six patients with both depression and epilepsy. Side effects were mild and temporary, and no worsening of seizures occurred. Four of the six patients showed a significant reduction in depression scores on the Montgomery-Åsberg Depression Rating Scale, with two achieving full remission. Three patients reported a subjective decrease in seizure activity over twelve months. No serious adverse events happened. The authors caution that this is a small, post-hoc observation and that larger prospective studies are needed to confirm effects on seizures, depression, and side effects.
A woman developed confusion, visual hallucinations, and ataxia after vaporizing synthetic cannabinoids. MRI imaging showed restricted diffusion and increased T2/FLAIR signal in the corpus callosum and cerebellar peduncles, indicating brain injury. This case highlights the potential neurological toxicities of synthetic cannabinoids.